What is HC Wainwright’s Estimate for Innoviva Q2 Earnings?

Innoviva, Inc. (NASDAQ:INVA) – Equities research analysts at HC Wainwright raised their Q2 2026 earnings estimates for shares of Innoviva in a report issued on Monday, June 1st. HC Wainwright analyst R. Selvaraju now expects that the biotechnology company will post earnings per share of $0.56 for the quarter, up from their prior estimate of $0.51. HC Wainwright currently has a “Buy” rating and a $46.00 target price on the stock. The consensus estimate for Innoviva’s current full-year earnings is $1.96 per share. HC Wainwright also issued estimates for Innoviva’s Q3 2026 earnings at $0.51 EPS and FY2026 earnings at $2.23 EPS.

Innoviva (NASDAQ:INVA) last posted its earnings results on Wednesday, May 6th. The biotechnology company reported $0.44 earnings per share for the quarter, beating analysts’ consensus estimates of $0.43 by $0.01. Innoviva had a net margin of 119.89% and a return on equity of 33.33%. The business had revenue of $97.99 million for the quarter, compared to analysts’ expectations of $101.57 million.

A number of other equities analysts have also recently issued reports on the company. Weiss Ratings reissued a “buy (b)” rating on shares of Innoviva in a report on Friday, March 27th. BTIG Research reaffirmed a “buy” rating and issued a $42.00 price target on shares of Innoviva in a research note on Tuesday, May 26th. Finally, Wall Street Zen cut Innoviva from a “buy” rating to a “hold” rating in a research report on Sunday, May 17th. Five research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $36.20.

Innoviva Stock Down 0.7%

Shares of INVA opened at $21.35 on Wednesday. The company has a quick ratio of 20.07, a current ratio of 21.13 and a debt-to-equity ratio of 0.19. The company has a 50-day moving average price of $22.89 and a two-hundred day moving average price of $21.76. The stock has a market cap of $1.58 billion, a price-to-earnings ratio of 3.55 and a beta of 0.35. Innoviva has a 12 month low of $16.52 and a 12 month high of $25.15.

Institutional Investors Weigh In On Innoviva

A number of large investors have recently bought and sold shares of the business. Parallel Advisors LLC raised its position in Innoviva by 82.8% in the 1st quarter. Parallel Advisors LLC now owns 1,179 shares of the biotechnology company’s stock valued at $27,000 after purchasing an additional 534 shares during the last quarter. EverSource Wealth Advisors LLC grew its holdings in shares of Innoviva by 297.7% during the second quarter. EverSource Wealth Advisors LLC now owns 2,398 shares of the biotechnology company’s stock worth $48,000 after purchasing an additional 1,795 shares during the last quarter. Danske Bank A S bought a new stake in shares of Innoviva during the third quarter worth $55,000. Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Innoviva by 49.1% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,633 shares of the biotechnology company’s stock valued at $73,000 after buying an additional 1,197 shares in the last quarter. Finally, Lazard Asset Management LLC bought a new position in shares of Innoviva in the second quarter valued at about $92,000. 99.12% of the stock is currently owned by institutional investors.

About Innoviva

Innoviva, Inc, incorporated in Delaware and headquartered in San Francisco, California, is a royalty-focused life sciences company. It acquires, manages and monetizes royalty and license interests in biopharmaceutical products, with a primary emphasis on inhaled respiratory therapies. Innoviva’s portfolio is anchored by royalties on therapies originally developed by its former affiliate, now marketed by GlaxoSmithKline, including several long-acting inhaled products approved for chronic obstructive pulmonary disease (COPD) and asthma.

The company was established through a spin‐out transaction in 2014, separating the royalty assets from a research‐based biopharmaceutical enterprise to create a specialized investment vehicle.